Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model

Genes

Volumn 7, Issue 9, 2016, Pages

  Gomis González, Maria ^a   Matute, Carlos ^b,c,d   Maldonado, Rafael ^a   Mato, Susana ^b,c,d   Ozaita, Andrés ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cannabinoid receptor; CB1; Endocannabinoid system; Fragile X syndrome; Long term depression; Memory; Synaptic plasticity; Treatment

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; NESS 0327; RIMONABANT; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FRAGILE X SYNDROME; LONG TERM DEPRESSION; LOW DRUG DOSE; MALE; MENTAL PERFORMANCE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST;

EID: 84985990254     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7090056     Document Type: Article

References (43)

1. Penagarikano, O.; Mulle, J.G.;Warren, S.T. The pathophysiology of fragile X syndrome. Annu. Rev. Genom. Hum. Genet. 2007, 8, 109-129. [CrossRef] [PubMed]
2. Verkerk, A.J.; Pieretti, M.; Sutcliffe, J.S.; Fu, Y.H.; Kuhl, D.P.; Pizzuti, A.; Reiner, O.; Richards, S.; Victoria, M.F.; Zhang, F.P.; et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65, 905-914. [CrossRef]
3. O’Donnell, W.T.; Warren, S.T. A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 2002, 25, 315-338. [CrossRef] [PubMed]
4. Jin, P.;Warren, S.T. New insights into fragile X syndrome: From molecules to neurobehaviors. Trends Biochem. Sci. 2003, 28, 152-158. [CrossRef]
5. Bear, M.F.; Huber, K.M.; Warren, S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27, 370-377. [CrossRef] [PubMed]
6. Michalon, A.; Sidorov, M.; Ballard, T.M.; Ozmen, L.; Spooren, W.; Wettstein, J.G.; Jaeschke, G.; Bear, M.F.; Lindemann, L. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012, 74, 49-56. [CrossRef] [PubMed]
7. D’Hulst, C.; Kooy, R.F. Fragile X syndrome: From molecular genetics to therapy. J. Med. Genet. 2009, 46, 577-584. [CrossRef] [PubMed]
8. Henderson, C.;Wijetunge, L.; Kinoshita, M.N.; Shumway, M.; Hammond, R.S.; Postma, F.R.; Brynczka, C.; Rush, R.; Thomas, A.; Paylor, R.; et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 2012, 4, 152ra128. [CrossRef] [PubMed]
9. Kano, M.; Ohno-Shosaku, T.; Hashimotodani, Y.; Uchigashima, M.;Watanabe, M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89, 309-380. [CrossRef] [PubMed]
10. Pacher, P.; Bátkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389-462. [CrossRef] [PubMed]
11. Marsicano, G.; Lutz, B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 1999, 11, 4213-4225. [CrossRef] [PubMed]
12. Varma, N.; Carlson, G.C.; Ledent, C.; Alger, B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 2001, 21, RC188. [PubMed]
13. Centonze, D.; Rossi, S.; Mercaldo, V.; Napoli, I.; Ciotti, M.T.; de Chiara, V.; Musella, A.; Prosperetti, C.; Calabresi, P.; Bernardi, G.; et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol. Psychiatry 2008, 63, 963-973. [CrossRef] [PubMed]
14. Olmos-Serrano, J.L.; Paluszkiewicz, S.M.; Martin, B.S.; Kaufmann, W.E.; Corbin, J.G.; Huntsman, M.M. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J. Neurosci. 2010, 30, 9929-9938. [CrossRef] [PubMed]
15. Suvrathan, A.; Hoeffer, C.A.; Wong, H.; Klann, E.; Chattarji, S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. USA 2010, 107, 11591-11596. [CrossRef] [PubMed]
16. Zhang, L.; Alger, B.E. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J. Neurosci. 2010, 30, 5724-5729. [CrossRef] [PubMed]
17. Jung, K.M.; Sepers, M.; Henstridge, C.M.; Lassalle, O.; Neuhofer, D.; Martin, H.; Ginger, M.; Frick, A.; DiPatrizio, N.V.; Mackie, K.; et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat. Commun. 2012, 3, 1080. [CrossRef] [PubMed]
18. Rinaldi-Carmona, M.; Barth, F.; Héaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Néliat, G.; Caput, D.; et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244. [CrossRef]
19. Christensen, R.; Kristensen, P.K.; Bartels, E.M.; Bliddal, H.; Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet 2007, 370, 1706-1713. [CrossRef]
20. Rucker, D.; Padwal, R.; Li, S.K.; Curioni, C.; Lau, D.C. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007, 335, 1194-1199. [CrossRef] [PubMed]
21. Landsman, R.S.; Burkey, T.H.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 1997, 334, R1-R2. [CrossRef]
22. Silvestri, C.; di Marzo, V. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin. Investig. Drugs 2012, 21, 1309-1322. [CrossRef] [PubMed]
23. Ruiu, S.; Pinna, G.A.; Marchese, G.; Mussinu, J.M.; Saba, P.; Tambaro, S.; Casti, P.; Vargiu, R.; Pani, L. Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 2003, 306, 363-370. [CrossRef] [PubMed]
24. Busquets-Garcia, A.; Gomis-González, M.; Guegan, T.; Agustín-Pavón, C.; Pastor, A.; Mato, S.; Pérez-Samartín, A.; Matute, C.; de la Torre, R.; Dierssen, M.; et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat. Med. 2013, 19, 603-607. [CrossRef] [PubMed]
25. Bhattacharya, A.; Kaphzan, H.; Alvarez-Dieppa, A.C.; Murphy, J.P.; Pierre, P.; Klann, E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76, 325-337. [CrossRef] [PubMed]
26. Sidhu, H.; Dansie, L.E.; Hickmott, P.W.; Ethell, D.W.; Ethell, I.M. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J. Neurosci. 2014, 34, 9867-9879. [CrossRef] [PubMed]
27. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22, 659-661. [CrossRef] [PubMed]
28. Wiley, J.L.; Burston, J.J.; Leggett, D.C.; Alekseeva, O.O.; Razdan, R.K.; Mahadevan, A.; Martin, B.R. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 2005, 145, 293-300. [CrossRef] [PubMed]
29. Zádor, F.; Lénárt, N.; Csibrány, B.; Sántha, M.; Molnár, M.; Tuka, B.; Samavati, R.; Klivényi, P.; Vécsei, L.; Marton, A.; et al. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner. Neuropharmacology 2015, 89, 298-307. [CrossRef] [PubMed]
30. Pertwee, R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005, 76, 1307-1324. [CrossRef] [PubMed]
31. Meye, F.J.; Trezza, V.; Vanderschuren, L.J.; Ramakers, G.M.; Adan, R.A. Neutral antagonism at the cannabinoid 1 receptor: A Safer treatment for obesity. Mol. Psychiatry 2013, 18, 1294-1301. [CrossRef] [PubMed]
32. Lee, S.H.; Ledri, M.; Tóth, B.; Marchionni, I.; Henstridge, C.M.; Dudok, B.; Kenesei, K.; Barna, L.; Szabó, S.I.; Renkecz, T.; et al. Multiple forms of endocannabinoid and endovanilloid signaling regulate the tonic control of GABA release. J. Neurosci. 2015, 35, 10039-10057. [CrossRef] [PubMed]
33. Palmer, M.J.; Irving, A.J.; Seabrook, G.R.; Jane, D.E.; Collingridge, G.L. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology 1997, 36, 1517-1532. [CrossRef]
34. Sanderson, T.M.; Hogg, E.L.; Collingridge, G.L.; Corrêa, S.A. Hippocampal mGluR-LTD in health and disease: Focus on the p38 MAPK and ERK1/2 pathways. J. Neurochem. 2016. in press. [CrossRef] [PubMed]
35. Huber, K.M.; Gallagher, S.M.; Warren, S.T.; Bear, M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 2002, 99, 7746-7750. [CrossRef] [PubMed]
36. Dölen, G.; Carpenter, R.L.; Ocain, T.D.; Bear, M.F. Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 2010, 127, 78-93. [CrossRef] [PubMed]
37. Osterweil, E.K.; Chuang, S.C.; Chubykin, A.A.; Sidorov, M.; Bianchi, R.;Wong, R.K.; Bear, M.F. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013, 77, 243-250. [CrossRef] [PubMed]
38. Busquets-Garcia, A.; Maldonado, R.; Ozaita, A. New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model. Int. J. Biochem. Cell Biol. 2014, 53, 121-126. [CrossRef] [PubMed]
39. Martín-García, E.; Burokas, A.; Martín, M.; Berrendero, F.; Rubí, B.; Kiesselbach, C.; Heyne, A.; Gispert, J.D.; Millán, O.; Maldonado, R. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J. Neurochem. 2010, 112, 1338-1351. [CrossRef] [PubMed]
40. Costa, L.; Sardone, L.M.; Lacivita, E.; Leopoldo, M.; Ciranna, L. Novel agonists for serotonin 5-HT7 receptors reverse metabotropic glutamate receptor-mediated long-term depression in the hippocampus of wild-type and Fmr1 KO mice, a model of Fragile X Syndrome. Front. Behav. Neurosci. 2015, 9, 65. [CrossRef] [PubMed]
41. Picone, R.P.; Kendall, D.A. From the bench, toward the clinic: Therapeutic opportunities for cannabinoid receptor modulation. Mol. Endocrinol. 2015, 29, 801-813. [CrossRef] [PubMed]
42. Thomas, A.; Baillie, G.L.; Phillips, A.M.; Razdan, R.K.; Ross, R.A.; Pertwee, R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br. J. Pharmacol. 2007, 150, 613-623. [CrossRef] [PubMed]
43. Till, S.M.; Asiminas, A.; Jackson, A.D.; Katsanevaki, D.; Barnes, S.A.; Osterweil, E.K.; Bear, M.F.; Chattarji, S.; Wood, E.R.;Wyllie, D.J.; et al. Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS. Hum. Mol. Genet. 2015, 24, 5977-5984. [CrossRef] [PubMed]